glp 1 agonist microdosing Benefits of GLP-1 GLP-1 (glucagon-like peptide-1) receptor agonists, such as tirzepatide (Zepbound) or semaglutide (Ozempic, Wegovy), are typically prescribed for diabetes and obesity management at standard therapeutic doses. Microdosing Can Microdosing GLP 1 Enhance

One that political scientists Donald Stokes called Pasteur's Quadrant

Arq Bras Endocrinol Metabol 2013;57:702-708

cardiovascular death, nonfatal myocardial infarct, nonfatal stroke) for the GLP-1RA albiglutide, efpeglenatide, dulaglutide, liraglutide, and semaglutide ( The GLP-1RA liraglutide has also been approved for the treatment of obesity at a higher standard dose (3 mg once daily) compared to the standard dose used for T2D treatment (1.2 mg once daily) due to the results of the SCALE study program (37, 38)

People who are obese (have a BMI greater than or equal to 30) are clinically eligible for GLP-1 drugs, but employer plans may set additional BMI requirements to cover GLP-1 drug use under obesity

But the story has moved quickly

Weight Management Program